Minimizing Non-adherence and Improving Compliance in Multiple Myeloma
Release Date: April 18, 2016
Expiration Date: April 18, 2017
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
In multiple myeloma (MM), the emergence of several oral agents and the increased use of maintenance/continuous therapy could result in more treatment non-adherence and therefore reduced efficacy. Patient-related, treatment-related and clinician-related factors can all contribute to non-adherence and should be understood by health care providers, the goal being to gauge the patient’s risk for inadequate dosing. This CE activity discusses the potential for non-adherence to myeloma therapy and aims to identify ways that clinicians can ameliorate this risk.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Summarize the impact of noncompliance with oral medication regimens in multiple myeloma on both prognosis and outcomes
- Identify strategies for improving compliance with medication regimens in myeloma patients who are prescribed oral therapy
Minimizing Non-adherence and Improving Compliance in Multiple Myeloma – Saad Z. Usmani, MD, FACP
Instructions for Participation and Credit
This activity is eligible for credit through April 18, 2017. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders Program
Director, Clinical Research in Hematologic Malignancies
Levine Cancer Institute/Carolinas Healthcare System
Charlotte, North Carolina
Clinical Professor of Medicine, UNC School of Medicine
Chapel Hill, North Carolina
Dr. Saad Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr. Usmani is a Clinical Professor of Medicine at the UNC School of Medicine, Chief of the Plasma Cell Disorder Program, and Director of Clinical Research in Hematologic Malignancies at the Levine Cancer Institute/Carolinas Healthcare System.
Dr. Usmani is a member of the International Myeloma Working Group, SWOG Myeloma Committee, American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), and the American Society of Bone Marrow Transplantation. He also serves on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, the ASH Committee on Plasma Cell Neoplasia, and the NCI Myeloma Steering Committee. Dr. Usmani is on the editorial review board of numerous medical journals, has authored/co-authored more than 80 peer-reviewed research manuscripts and 100 abstracts at national and international meetings. A specialist in hematology, medical oncology and bone marrow transplantation, Dr. Usmani’s clinical and translational research has been focused on plasma cell disorders, specifically high-risk multiple myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-076-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Saad Usmani has disclosed no relevant financial relationships.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Usmani has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Usmani has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.